Grégory Catteau

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age: Results From a Randomized Open Trial

C. Wheeler, M. Pichichero, G. Dubin, 2011, The Pediatric infectious disease journal.

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

P. Naud, B. Geeraerts, J. Teixeira, 2014, Human vaccines & immunotherapeutics.

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

P. Hillemanns, M. Dionne, T. Schwarz, 2011, Human vaccines.

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

M. Lehtinen, S. Garland, X. Castellsagué, 2016, International journal of cancer.

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.

S. Wacholder, A. Hildesheim, R. Herrero, 2014, Vaccine.

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

M. Einstein, M. Levin, F. Struyf, 2014, Human vaccines & immunotherapeutics.

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

A. Schneider, T. Schwarz, D. Descamps, 2011, Human vaccines.

Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.

E. Jongert, A. Leach, M. Lievens, 2014, Vaccine.